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Abstract
Sepsis and meningitis due to invasive group B Streptococcus (iGBS)
disease during early infancy is a leading cause of child mortality.
Recent systematic estimates of the worldwide burden of GBS
suggested that there are 319,000 cases of infant iGBS disease each
year, and an estimated 147,000 stillbirths and young-infant deaths,
with the highest burden occurring in Sub-Saharan Africa. The
following priority data gaps were highlighted: (1) long-term outcome
data after infant iGBS, including mild disability, to calculate qualityadjusted life years (QALYs) or disability-adjusted life years (DALYs) and
(2) economic burden for iGBS survivors and their families. Geographic
data gaps were also noted with few studies from low- and middleincome countries (LMIC), where the GBS burden is estimated to be the
highest. In this paper we present the protocol for a multi-country
matched cohort study designed to estimate the risk of long-term
neurodevelopmental impairment (NDI), socioemotional behaviors,
and economic outcomes for children who survive invasive GBS disease
in Argentina, India, Kenya, Mozambique, and South Africa. Children
will be identified from health demographic surveillance systems,
hospital records, and among participants of previous epidemiological
studies. The children will be aged between 18 months to 17 years. A
tablet-based custom-designed application will be used to capture data
from direct assessment of the child and interviews with the main
caregiver. In addition, a parallel sub-study will prospectively measure
the acute costs of hospitalization due to neonatal sepsis or meningitis,
irrespective of underlying etiology. In summary, these data are
necessary to characterize the consequences of iGBS disease and
enable the advancement of effective strategies for survivors to reach
their developmental and economic potential. In particular, our study
will inform the development of a full public health value proposition
on maternal GBS immunization that is being coordinated by the World
Health Organization.
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Introduction

The United Nations Sustainable Development Goals (SDGs)
aim to complete the unfinished agenda for child survival and
ensure that every child has the opportunity to thrive, including
reaching their developmental potential1,2. While SDG3 continues to center on the reduction of neonatal and child mortality,
SDG4 incorporates specific targets and indicators to address
early childhood development (UN SDG, 2015). It is recognized
that preventable infections, such as those that cause meningitis, neonatal sepsis, and pneumonia, are an important cause of
neonatal and infant death3. However, their contribution to neurodevelopmental impairment (NDI), which encompasses both
developmental delay (two or more developmental domains in
children ≤5 years old) and disability (impairment in a child’s
physical, learning, language, or behavior function) has been
under-appreciated. As child deaths are reduced in low- and middle-income countries (LMIC), neurodevelopmental impairment
may increase, especially if access and quality of early childhood
developmental programs is sub-optimal4,5.
Invasive group B Streptococcus (iGBS) disease during the first
months of life is one of the infections that might have important long-term consequences for children. This infection often
presents as sepsis or meningitis and was responsible for an estimated 90,000 (uncertainty range [UR]: 36,000-169,000) infant
deaths in 20156. Survivors of iGBS disease in early life may
develop long-term NDI. Of 18 studies identified in a recent review
of the risk of NDI in children with history of iGBS disease7,
only three were from middle-income countries and none were
from low-income countries where the majority of iGBS disease cases occur. In these studies, NDI was defined as problems
of body function and structure, such as significant deviations or
loss in intellectual and/or motor, vision, or hearing impairment.
The review concentrated on infants with GBS meningitis, highlighting a key data gap related to long-term adverse outcomes
in infants who develop GBS-associated sepsis. Furthermore,
only a small number of older studies (primarily from the 1970s)
reported NDI outcomes in children older than 2 years, which
would have missed impairment outcomes that do not manifest
until later in childhood.
Intrapartum antibiotic prophylaxis (IAP) has reduced the incidence of early-onset iGBS disease in some high-income countries8,9; however, this approach is less effective in preventing
late-onset invasive disease10 and thought not to significantly
affect other consequences of maternal GBS colonization, notably
GBS-associated stillbirths and preterm births. Maternal vaccination against GBS is a promising alternative that could protect
both mothers and infants against iGBS disease. To guide investment in maternal vaccines targeting GBS, it is necessary to estimate the health and economic burden caused by the disease
globally11. Studies on mortality and morbidity due to GBS among
pregnant and postpartum women, stillbirths, and infants have
been recently reviewed and meta-analyzed12. These reviews uncovered two major data gaps that significantly hinder these analyses:
the lack of long-term follow-up data amongst survivors, which
are needed to calculate generic health-related utility measures
such as quality-adjusted life years (QALYs) or disability-adjusted

life years (DALYs) to allow comparison with other diseases,
and the lack of primary data regarding long-term economic consequences to households of children with a history of iGBS
disease.
Data on the costs associated with iGBS disease, which are
needed to inform cost-effectiveness analysis and investment
decisions on the development and deployment of new vaccines,
are scarce. We are only aware of a single study undertaken in
the UK that directly assessed the economic costs of iGBS disease beyond the acute episode13. This showed that over the first
two years of life, the health and social care costs of infants with
a history of iGBS disease were almost twice that of children with
no history of iGBS disease. Although there are more studies that
report on the acute costs of infant sepsis/meningitis, these are
generally from high-income countries and are not GBS etiology specific14. To better understand the life-course consequences
of infant iGBS, data on health and economic outcomes needs to
be collected in studies that include older children and adolescents
across multiple settings.
In this paper, we present the protocol for a multi-country epidemiological study. The main aim of the study is to estimate the
risk of NDI and socioemotional behaviors in children who survived neonatal or infant iGBS. The study will also measure
long-term health related quality of life (HRQoL) and economic
costs that arise as a consequence of iGBS, as well as the acute
costs of sepsis and meningitis in young infants. This study,
coordinated by the London School of Hygiene & Tropical Medicine, is part of a collaboration with the World Health
Organization (WHO) to inform the development of a value
proposition for maternal vaccines against GBS.

Research objectives
Our objectives in designing this study were:
Objective 1 - Long-term neurodevelopmental impairment:
(a) Primary objectives:
1. To estimate the risk of moderate/severe NDI in children with history of iGBS disease in early-infancy,
and to compare this with the risk in children with
no known history of iGBS
2. T
 o estimate the risk of mild and moderate/severe
socioemotional behavior outcomes in children
with history of iGBS, and compare with risk in
children with no known history of iGBS
(b) Additional objectives:
1. To estimate the risk of mild impairment
2. T
 o estimate the risk of multi-domain and domainspecific neurodevelopmental impairment
3. T
 o estimate the risk of adverse growth outcomes
(e.g., stunting, wasting)
4. To estimate the risk of epilepsy
Objective 2 – Long-term mortality: To assess mortality beyond
initial hospital-discharge among children who had iGBS.
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Objective 3 – Long-term economic costs and health-related
quality of life:
(a) Long-term economic consequences: To measure the
long-term economic costs to the healthcare system,
households and society associated with infant iGBS.
(b) Health-related quality of life: To collect information
needed to calculate the difference in QALYs between
children with a history of iGBS, and those with
no history of iGBS.
Objective 4 – Short-term economic consequences: To estimate the costs to the healthcare system and households during
acute episodes of sepsis and meningitis (irrespective of etiology)
in neonates and young infants.

Protocol
Study design

Long-term outcomes after iGBS disease in infancy (Objectives
1, 2, 3). We will use a matched cohort study design to collect
data on NDI, socioemotional behavioral, and economic outcomes for survivors of iGBS in early infancy. Children with
a history of infant iGBS (henceforth iGBS survivors), will
be identified via hospital records in study sites, Health and
Demographic Surveillance Systems (HDSS), or among participants of previous epidemiological studies. Children with no history of iGBS (henceforth, the non-iGBS comparison group)
will be identified and matched to iGBS survivors based on
sex and birth month and year.
Acute costs of neonatal sepsis and meningitis study (Objective 4). In addition to the main study measuring long-term
economic outcomes, we will undertake a separate study to
quantify the acute costs to the healthcare system and household
linked to neonatal sepsis and meningitis. This study will involve
a different study population: prospectively identified neonates
admitted for clinically suspected sepsis or meningitis irrespective of the underlying etiology. Data on the costs associated with
the period of acute hospitalization will be collected following
discharge.

Study settings and teams
Since the major data gap on the long-term outcomes of iGBS
survivors is in LMICs, this study was designed to collect data
in these settings, including at least one country per GBS highburden region (Africa, Asia, Latin America). For this collaborative work, we shared a call for data through multiple
channels in 2018, including targeting previous collaborators,
experts and known GBS researchers, scientific conferences and
meetings, as well as sending direct requests from WHO headquarters to country offices and placing posts on social media
platforms to reach the widest number of people. With these various approaches we aimed to ensure better geographical representation than currently seen in the literature. Among those who
responded, potential study sites were identified based on the
following criteria: (a) sites that had at least 10 post-discharge
surviving iGBS cases that could be enrolled; (b) sites that had
neurodevelopmental follow-up data or the ability to collect this

type of data in children aged at least 3 years; (c) sites where the
expected loss to follow-up was <20%. From those who expressed
an interest in joining this project and fulfilled the above criteria, research teams from Argentina, India, Kenya, Mozambique and South Africa agreed participate in this work and lead
investigations locally (Table 1).
In Argentina, the local study will be performed by the research
organization Fundación Infant, in Buenos Aires; in Southeast
India, the research activities are led by the Christian Medical
College in Vellore; in Kilifi, Kenya, the work is being undertaken by KEMRI-Wellcome Trust Research Programme; in
Mozambique, children are being recruited at the Manhiça Health
Research Centre, in collaboration with the Barcelona Institute
for Global Health; and in South Africa, the project is being led
by the South African Medical Research Council Vaccines and
Infectious Diseases Analytical Research Unit (VIDA).

Long-term health outcomes after GBS invasive disease
in infancy (Objectives 1, 2 & 3)
Study populations. In the Kenya and Mozambique sites, which
are also HDSS sites, parents of potential study participants,
based on the HDSS database, will be contacted through standard recruitment procedures. Hospital records, which are linked
to the HDSS database, will be used to identify all children who
have been admitted with iGBS based on the case definition. The HDSS database will also be used to select matched
non-iGBS children from the community.
In Argentina and India, hospital-based databases will be
used to identify potential iGBS survivors and non-iGBS
children using standard practices established by each site.
Hospital-based databases will be used to identify children who
have been admitted with iGBS based on the case definition.
Hospital-based birth registries will be used to select matched
non-iGBS children.
In South Africa, the same cohort of iGBS survivors and controls from three epidemiological studies that were conducted
between 2012 and 2015 will be contacted for re-enrolment.
These participants are expected to be 5–7 years old and originally consented to be followed until the age of 5. Using the
study database, parents or primary caregivers of these children
will be contacted by phone for interest and be given information
about participating in the new study.
Invasive GBS disease case definition. Children with a previous diagnosis of either GBS meningitis or GBS sepsis in the
first 90 days of life (days 0 - 89) will be recruited in these local
epidemiological studies. Enrolment of children with a history
of GBS sepsis is important to increase the, currently limited,
number of studies with data on long-term disability post-GBS
sepsis7. Table 2 below summarizes the case definition and the
clinical and microbiological eligibility criteria used by each
study site for identification of exposed children in this study.
Sample size and power calculation. The number of iGBS survivors included in the matched cohort study of long-term
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Table 1. Description of collaborative research partners and study population participating in long-term and acute cost
studies.
Long-term outcomes study (Objectives
1,2,3)

Country
of data
collection

Collaborative
Institute(s)

Facility type

Argentina

Fundación
Infant,
Buenos Aires,
Argentina

India

Christian
Medical
College (CMC)
Vellore, Tamil
Nadu, India

Kenya

KEMRIWellcome
Trust, Kilifi,
Kenya
Barcelona
Institute for
Global Health,
Barcelona,
Spain

Mozambique

South Africa

Manhiça
Health
Research
Centre,
Manhiça,
Mozambique

Wits Health
Consortium,
Johannesburg,
South Africa

Identification
of GBSexposed
children

Identification
of GBSunexposed
children

2 Public
hospitals in
Tucuman area

Neonates
admitted with
GBS sepsis
or meningitis
from 2003–
2016

Primary Care
Centers that
belong to
the Maternity
Network

Academic
and referral
hospital at
CMC Vellore

Hospitaldelivered
neonates
admitted from
2004–2018

Hospital birth
registry

Admitted with
GBS from
2007–2018

Health
Demographic
Surveillance
System

Kilifi County
Hospital /
KEMRI

Age at
enrolment

Acute cost study (Objective 4)
Identification of
meningitis/sepsis

Age at
enrolment

N/A

N/A

3–16 years

Sepsis with positive
blood culture.

Manhiça
District
Hospital

Isolated
during routine
morbidity and
microbiological
surveillance
conducted
2001–2018

Health
Demographic
Surveillance
System

3 Academic
hospital in
Johannesburg

Surveillance of
the pediatric
wards and
microbiology
services at the
three hospitals
from 2012–
2015

Unexposed
children
enrolled
during
a similar
time-period
as exposed
children

18 months
– 15 years

Meningitis with either
positive CSF culture
or suggestive CSF
counts or protein
Sepsis with positive:
blood culture

1–12 years

Meningitis with
positive CSF culture
or suggestive CSF
counts or protein
Sepsis with positive
blood culture or
clinically presumed
sepsis

3–17 years

0–89 days
old

Meningitis with
positive CSF culture
or suggestive CSF
counts or protein; or
clinically presumed
meningitis
Sepsis with positive
blood culture

5–7 years

Meningitis with
positive CSF culture,
latex agglutination,
PCR or suggestive
CSF counts

Table 2. Case definition of invasive GBS disease used for recruitment (adapted from 15).
Clinical syndrome

Case definition used in this study

Possible serious
bacterial infection
(pSBI)

Any one of the following: a history of difficulty feeding, history of convulsions, movement only when
stimulated, respiratory rate of 60 breaths per min or more, severe chest in-drawing, temperature ≥
37.5°C or ≤35.5°C

Sepsis

Clinical signs of pSBI and/or GBS-positive blood culture or PCR or latex agglutination

Meningitis

Clinical signs of pSBI and [(GBS-positive CSF culture or PCR or latex agglutination) or (GBS-positive
blood culture or PCR or latex agglutination and CSF leucocyte count of >20x106/l)]

pSBI, possible serious bacterial infection; CSF, cerebrospinal fluid; PCR, polymerase chain reaction.
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outcomes was based on the maximum number of cases expected
to be identified, accounting for 20% being unreachable, ineligible
or who refuse participation. The expected number of iGBS survivors for each site is summarized in Table 3. Based on anticipated
recruitment of 200 iGBS survivors and a 1:3 ratio of matched
non-iGBS children, and assuming a prevalence of our primary
outcome (moderate/severe NDI) of 26% in iGBS survivors and
10% in the non-iGBS comparison group (based on a study of
meningococcal serogroup B survivors16), a pooled analysis would
be able to detect this difference using a two-sided test of binomial proportions with 99% power at a 5% significance level.
Mild developmental impairment is likely to be more prevalent
among iGBS survivors, including those with sepsis. Our power
to detect a difference in the risk of overall NDI (including mild
NDI) would be 78%, assuming detection of 32% and 20%
NDI in iGBS survivors7 and non-iGBS children17, respectively.
Study procedures and data collection. Trained fieldworkers
will contact the parents/primary caregivers of these potential
participants about the study by phone (Argentina, India, South
Africa) or in-person (India if phone contact information is not
available, Kenya, Mozambique) and those contacted will be

Table 3. Expected number of children with
history of iGBS, by site, for the long-term
outcomes study.
Site/Country

Expected number children
with history of iGBS

Argentina

40

India

30

Kenya

50

Mozambique

40

South Africa

40

asked to make a one-time visit to the health facility with their
child. Reasons for non-participation, such as migration, refusal
or death will be recorded.
Children enrolled in the study and their main caregiver will
receive an in-person assessment visit. Written informed consent will be obtained in-person either at the time of the initial house visit or before the in-person assessment visit. Only
if appropriate consent/assent is obtained, will the child be enrolled
in the study.
At the in-person assessment visits, the following information
will be collected:
- Questionnaire to collect participant details including birth
and medical history, education, household demographic
and socioeconomic data, as well as economic outcomes
(for details on economic outcomes see section Economic
outcomes and health related quality of life)
- A
 ge-specific neurodevelopmental assessment tools including several domains (motor, vision, hearing, cognitive,
language, socioemotional), an epilepsy screening questionnaire, and anthropometric measures (see section on
Assessment of developmental outcomes)
- E
 Q-5D-3L questionnaires to assess the health-related
quality-of-life (HRQoL) of study participants and their
main caregiver (see section Economic outcomes and
health related quality of life).
Data will be collected on paper forms or using a customized
app (developed in collaboration with icddr,b, Bangladesh). The
customized Android tablet-based app includes questionnaires
and neurodevelopment assessment tools, translated into local
language where relevant (Figure 1).
Assessment of neurodevelopmental impairment (Objective 1).
In this multi-country study, we will use several tools to diagnose

Figure 1. Screenshots from the customized data capture app.
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NDI and socioemotional and behavioral outcomes in children
over a wide age range from 18 months to 17 years old.
The inclusion of children older than those enrolled in the majority of the previous epidemiological studies enables us to use
more complex developmental assessments designed for older
ages to detect specific mild NDI and other developmental delays.
By including a wider age range, we can also better understand the developmental trajectory of infants who have survived
iGBS. The developmental domains of interest are motor, vision,
hearing, cognitive, language, and socioemotional; their definitions, by severity, are described in the Data analysis section.
We will also explore growth outcomes and epilepsy.

The diagnostic tools used to identify NDI and other developmental measurements will be administered by experienced
assessors, clinical psychologists and pediatricians, who will also
perform clinical exams to identify impairment in hearing, motor
and vision domains. Each local research team decided which
neurodevelopmental assessment tools are appropriate for their
setting, based on child’s age and cultural appropriateness or
validation of the instrument and technical capacity of each site.
There will be 26 different assessment tools and tests being used
across the 6 neurodevelopmental domains, as well as anthropometric measurements for growth and an epilepsy screening questionnaire. Table 4 shows the matrix of assessments for

Table 4. Neurodevelopment assessment tools and other developmental assessment
measures, by site and age.
Sites
Argentina

India

Kenya

Mozambique

South
Africa

Pediatric
clinical exam

BSID*

KDI*

MDAT

N/A

Bolts and Nuts

CANTAB

GMDSER

Motor
< 5 years old

5 – < 10 years old

BOT‡
BOT‡

Bead Threading
≥ 10 years old

Stork Balance

N/A

Ball Balance
Cognition
< 5 years old

5 – < 10 years old

≥ 10 years old

WPPSI†

BSID*

KDI*

WPPSI†

Big/small stroop

WPPSI

WPPSI

RCPM

WISC 4¥

WISC 5¥

Tower of London

WISC 4¥

WISC 5¥

RCPM

†

†

MDAT

N/A

CANTAB

GMDSER
N/A

Trail Making
Language
< 5 years old

WPPSI†

BSID*

KDI*
PVT,
Measures of pragmatics

MDAT

N/A

5 – < 10 years old

WPPSI†

WPPSI†

Kilifi Naming Test

CANTAB

≥ 10 years old

WISC 4¥

WISC 5¥

Measure of Pragmatics
and Syntax

GMDSER
N/A

Hearing
≤ 4 years old
> 4 years old

Screening test: Distraction test
Further testing: ABR

N/A

Screening test: Tuning fork, Diagnostic memory audiometer
Further testing: ABR
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Sites
Argentina

India

Kenya

Mozambique

South
Africa

Vision
≤ 3 years old
> 3 years old

LEA symbols Chart or Picture chart

N/A

Visual acuity app/Tumbling E chart/Snellen chart

Socioemotional
≤ 6 years old

CBCL-preschool

> 6 years old

CBCL- school aged

Epilepsy
All ages

Epilepsy Screening Questionnaire (ESQ)

*BSID assessment up to 42 months.
†

WPPSI assessment in Argentina 3-7 years. WPPSI assessment in India 4-7 years.

‡

BOT assessment ≥4 years.

¥

WISC 4 and WISC 5 assessment ≥7 years.

ABR, auditory brainstem response; BOT, Bruininks-Oseretsky Test; BSID, Bayley Scales of Infant and Toddler
Development;
CANTAB, Cambridge Neuropsychological Test Automated Battery; CBCL, Child Behavior Checklist; GMDS-ER, Griffiths
Mental
Development Scales – Extended Revised; KDI, Kilifi Developmental Inventory; MDAT, Malawi Developmental
Assessment Tool; PVT, Picture Vocabulary test; RCPM, Raven’s colored progressive matrices; WISC, Wechsler
Abbreviated Scale of Intelligence; WPSSI, Wechsler Preschool and Primary Scales of Intelligence.

each developmental domain, by age category and study site.
When a need for further assessment and clinical management
is identified, children will be appropriately referred into each
site’s existing referral systems.
Mortality outcome (Objective 2). Whenever feasible, data on
the cause of death will be captured through a variety of methods, including by reviewing medical records, verbal autopsy
reports and interviews with parents, for iGBS survivors who
died after the acute episode and before enrolment and for
matched non-iGBS group who died. In Kenya, the list of
iGBS survivors who could potentially be enrolled in the study
only included children alive at the time of enrolment, therefore
data on early mortality post-iGBS disease will not be collected in
these sites.
Long-term economic costs and health-related quality of life
outcomes (Objective 3). There are only limited data available on the economic consequences of iGBS, which cover only
healthcare costs in the first two years of life14. In this study, we
will collect information on variables that will allow comparisons of economic outcomes in families of iGBS survivors versus
families of the non-iGBS comparison group. These data will also
be used to inform future economic analyses that will be performed
to assess the value of maternal vaccines against iGBS.
A summary of key economic variables is shown in Table 5.
Information collected will include details of the monthly

household income and expenditure, participating children’s
healthcare utilization, out-of-pocket payments, and any expenditure on social care or special education in the 12 months preceding study enrolment. Additionally, information will be collected
on time spent by the main caregiver providing informal care
to the participant, as well as information on the costs of coping
strategies, such as borrowing and asset sales. Information on the
HRQoL of both the participant and the main caregiver will
be collected using an EQ-5D-3L questionnaire in three countries where country-approved translations are available: Argentina (Spanish), India (English, Telugu, Tamil) and South Africa
(English, Zulu).

Acute costs of neonatal sepsis and meningitis
(Objective 4)
Case definition for neonatal sepsis and meningitis. To be able
to collect data on acute costs, both cases of severe neonatal infection linked to GBS and cases of severe neonatal infection due
to other bacteria will be enrolled, as the number of confirmed
iGBS cases per hospital is anticipated to be small over the duration of our study. Participants will be babies admitted with a
diagnosis of clinically suspected neonatal infection (sepsis or meningitis) combined with isolation of a pathogenic microbiological
agent by culture or detection by polymerase chain reaction
(PCR) in a normally sterile site (blood/CSF) on day 0 – 89 of
an infant’s life. Babies born at <32 weeks of gestational age,
born with severe congenital abnormalities, or with culture positive results only for organisms considered to be contaminants
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Table 5. Economic data to be collected as part of the long-term and acute cost studies.
Category

Measures

Acute

Longterm

Participant characteristics

Participant details including date of birth, gender and ethnic group.
Relevant medical history including HIV status, gestational age at birth, and
birthweight.
Educational status.

Yes

Yes

Caregiver characteristics

Age, gender, and relationship to the child.
Education level and occupation.

Yes

Yes

Household characteristics

Number, relationship to patient and ages of other household occupants.
Education level and occupation of head of household and mother.
Household income and welfare received.
House-hold socioeconomic status based on local asset index.
Household location (urban / rural).

Yes

Yes

Healthcare resource use
during acute episode

Length-of-stay by bed type (e.g. ICU vs general bed) and days of supportive care
(e.g. ventilation, NG tube, Oxygen, IV fluids).
Diagnostics (e.g. lumbar puncture, blood tests, blood/CSF cultures, diagnostic
imaging) and medicine use.

Yes

No

Household expenditure

Total household expenditure including separate expenditure on health, transport,
education, and food.

Yes

Yes

Participant HRQoL

For long-term cohorts a self-reported EQ-5D-3L for children aged 11 and over; a
proxy-reported EQ-5D-3L for children aged 3 to 11.
For the acute cost study, a proxy-reported Visual Analogue Scale.

Yes

Yes

Caregiver HRQoL

A self-reported EQ-5D-3L.

Yes

Yes

Participant healthcare &
out-of-pocket payments

Number of visits and number of days admitted to a hospital.
Number of visits to healthcare facilities or traditional healers, and home visits by
community healthcare professionals.
Out-of-pocket payments on healthcare including drug costs, travel and
accommodation and caregiver time spent accompanying participants to hospital.

Yes

Yes

Participant social care & outof-pocket payments

Use of and cost of special educational services.
Use of and cost of professional care in the home.
Provision and cost of any home modifications.

No

Yes

Informal caregiving

Time spent by the main caregiver providing care to the participant.
Amount of paid work, subsistence work, housework foregone due to caregiving.

No

Yes

Cost of coping

Borrowing to cover healthcare and social care costs, or as the result of being
unable to work.
Value of assets sold to cover costs.
Other coping mechanisms.

Yes

Yes

or skin commensals will be excluded (Table 6). In Mozambique
the cases will be defined based on clinically suspected sepsis
or meningitis because the number of bacteriologically confirmed cases is anticipated to be low due to the size of the
hospital.
Sample size. At least 20 participants will be recruited in each of
the four sites. The sample size of 20 per site was set as a practical minimum, considering both available resources and
also a consensus by local research teams that this would be a
feasible number to capture given the anticipated number of
neonatal infections within the timeframe of data collection
activities.

Study procedures. Participants will be identified prospectively
either on admission or using clinical databases. Additionally,
in India recent cases (within three months before the start of
the study) will also be identified retrospectively from clinical
records. Details on hospital resource use will be collected from
medical records, including information on length-of-stay, type
of hospital bed, and details of any drugs, diagnostic tests and
surgical procedures. To capture the wider impacts of a participant’s hospitalization, a questionnaire will be administered to the
main caregiver, either at time of discharge, or by follow-up as
soon as possible after discharge, to collect details on household
demographics and economic impact. This will include any
out-of-pocket payments, costs related to travel, accommodation,
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Table 6. Selected organisms considered possible
contaminants or skin commensals for neonatal
infection (non-exhaustive list).
Excluded organism
Coagulase-negative Staphylococcus
Bacillus spp.
Micrococcus spp.
Corynebacterium spp.
Propionibacterium spp.
Diphtheroids
Aerococci
Brevundimonas vesicularis
Ochrobactrum anthropi
Staphylococcus saprophyticus
Burckholderia/ NFGNB (if in first three days of life)
Enterococcus (if baby asymptomatic)
Cultures which show poly-microbial growth
(unless baby has had abdominal surgery / or if it
includes GBS/E coli)
Any bacterium which shows growth after 72 hours
of life

and caregiver time. Data will be gathered on the main caregiver’s
HRQoL using an EQ-5D-3L questionnaire and the main
caregiver will be asked to estimate their child’s HRQoL during
their time in hospital using a Visual Analog Scale (VAS). The
main caregiver will be encouraged to accompany the child to the
assessment visit, but in the cases where they do not then these
sections of the questionnaire will not be completed. No questionnaires will be administered in the case that a participating
child dies in hospital, but data will still be collected from
hospital records.

Data management
Data will be stored on secure servers locally after the end
of the study, and anonymized data will be transferred to the
team at the London School of Hygiene & Tropical Medicine,
where data from different countries will be pooled. Analyses
will be conducted jointly by all study partners.
Analysis plan
Objective 1 - Long-term neurodevelopmental impairment. To
allow comparison between the different neurodevelopmental
assessments being used in each of the five sites, we will undertake a mapping activity across all 26 tools by age bands (1–4,
5–9, 10+). The age bands are constructed based on key periods of
development15. We will map similar constructs across the different assessments; e.g., gross motor measurements from all relevant tools will be mapped against each other allowing us to
compare gross motor development across sites. We will do this
for the following domains; gross motor, fine motor, cognitive

and language. We will also do a similar mapping activity
between the preschool and school-aged CBCL for the socioemotional and behavioral outcomes (e.g., anxiety, ADHD, and autism).
Definitions domain-specific neurodevelopmental impairment
and severity are described in Table 7.
In India, Kenya, Mozambique, and South Africa, motor and
cognitive scores will be normalized using standard reference populations by assessment and site. In Argentina, where
motor impairment is being assessed through a clinical exam,
description of functional impact will be used.
Vision impairment will be defined using WHO categories of
mild (visual acuity in best eye ≤6/12), moderate (visual acuity in best eye ≤6/18 and >6/60), severe (visual acuity in best
eye ≤6/60 and >3/60), and blindness (visual acuity in best eye
≤3/60)18,19.
Any hearing impairment will be defined as an unaided hearing threshold in the best ear of >26 decibels and further categorized into mild (audiometric hearing threshold level 26–30
decibels), moderate (threshold level 31–60 decibel), and severe/
deafness (threshold level >60 decibel)18,20. In South Africa
and Mozambique, screening tests will be used first to identify any individual with any potential hearing impairment.
Results from further diagnostic tests will be used to classify into
impairment severity as categorized above.
Socioemotional behavior measures will be defined in all sites
using the CBCL assessment. The main scoring is based on a
principal components analysis that grouped sets of behaviors
into different syndrome scales: (1) internalizing problem scales,
which include anxious/depressed, withdrawn-depressed, and
somatic complaints scores; and (2) externalizing problem scales,
which includes rule-breaking and aggressive behavior. There
is also a total problem score which is the sum of all the items.
Each syndrome, internalizing and externalizing problem score,
and total score can be categorized into normal (<93rd percentile), borderline (93rd-97th percentile), or clinical behavior
(>97th percentile) based on the same normative samples to create
standard scores based on sex and age for all sites.

Primary outcomes
There are 2 primary outcomes in this study, moderate/severe
NDI and moderate/severe behavioral outcomes.
Moderate/severe NDI will be defined as:
- Score of >2 SD below the standardized reference mean
in cognition AND/OR motor composite measures
- AND/OR hearing loss
- AND/OR vision loss
Moderate/severe behavioral outcomes will be defined by scores
within clinical ranges of ≥1 domain(s) of the problem scales.

Additional outcomes
Mild NDI (including socioemotional behavior outcomes) will
be defined as:
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Table 7. Definitions of growth and domain specific neurodevelopmental impairment severity.
Domain and severity

Severity definition used in this study

Motor

Mild

Motor for age Z-score -1 to -2 SD for test OR outside normal range of standardized motor score
for mild classification OR no functional motor impairment from physical exam

Moderate

Motor for age Z-score -2 to -3 SD for test OR outside normal range of standardized motor score
for moderate classification OR moderate functional motor impairment from physical exam

Severe

Motor for age Z-score ≤3 SD for test OR outside normal range of standardized motor score for
severe classification OR moderate functional motor impairment from physical exam such as
cerebral palsy

Mild

Cognitive for age Z-score -1 to -2 SD for test (DQ 70-84)

Moderate

Cognitive for age Z-score -2 to -3 SD for test (DQ 55-69)

Severe

Cognitive for age Z- score ≤3 for test (DQ <55)

Mild

Language for age Z-score -1 to -2 SD for test OR outside normal range of standardized language
score for mild classification

Moderate

Language for age Z-score -2 to -3 SD for test OR outside normal range of standardized language
score for moderate classification

Severe

Language for age Z-score ≤3 SD for test OR outside normal range of standardized language score
for severe classification

Mild

Visual acuity in best eye <6/12 but better or corresponding visual field loss

Moderate

Visual acuity in best eye between 6/18 and 6/60, or corresponding visual field loss

Severe

Visual acuity in best eye between 6/60 and 3/60, or corresponding visual field loss

Blindness

Visual acuity in best eye <3/60, or corresponding visual field loss

Mild

Audiometric hearing threshold level 26-30 decibel

Moderate

Audiometric hearing threshold level 31-64.9 decibel

Severe or
deafness

Audiometric hearing threshold level ≥65 decibel

Mild

CBCL scores within borderline clinical range in at least one domain of the problem scales

Moderate or
severe

CBCL scores within clinical range ≥1 domain(s) of the problem scales

Intellectual

Language

Vision

Hearing

Socioemotional/
behavioral

Epilepsy
Growth

Had at least one seizure in the last month
Stunted

Height for age Z-score < -2

Underweight

Weight for age Z-score < -2

Head
circumference

Head circumference for age Z-score < -2

- S
 core of 1-2 SD below the standardized reference mean
in cognition AND/OR motor composite measures
- AND/OR mild hearing loss
- AND/OR mild vision loss
- A
 ND/OR borderline clinical range in at least one domain
of the problem scales from the CBCL
We will further assign individuals into the following multidomain impairment categories based on severity (adapted from21):

- Mild if child is classified as mildly impaired in ≤2 domains
- M
 oderate if child is classified as mildly impaired in
3 domains OR classified as moderately impaired in 1
domain & classified as mildly impaired in 2 domains
- S
 evere if child is classified as moderately impaired in
≥2 moderate domains OR severely impaired in ≥2 domains
The distribution of mild and moderate/severe neurodevelopmental outcomes will be summarized for children with history of iGBS disease and the non-iGBS comparison group and
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further stratified by clinical syndrome (sepsis and meningitis).
We will test the association between history of iGBS disease in
early-infancy and moderate/severe NDI in a pooled analysis using a logistic regression accounting for matching factors
of age and sex. As gestational age is likely to be an important
confounder, we will adjust for this, if the data allows.
Objective 2 - Mortality. For iGBS survivors, and their matched
non-iGBS comparison group, that were reachable (i.e. for whom
we have information), we will describe the proportion of children who died before enrolment in each site. Where available, we will also describe the causes of death in both iGBS and
non-iGBS groups.
Objective 3 - Long-term economic and health-related quality of life. We will assess the impact of iGBS on economic
outcomes including healthcare utilization and costs, household
out-of-pocket payments, household income and social care payments, and time spent by the main caregiver on informal care.
The cost of hospital stays and attending outpatient clinics will
be estimated using published unit costs (e.g. WHO-CHOICE)22.
We will compare these outcomes between the iGBS and noniGBS groups in each study site. If data allow, we will also analyze differences in costs and healthcare utilization linked to
NDI. Information from EQ-5D-3L questionnaires will be used
to estimate differences in QALYs of both children and their
caregivers associated with a history of iGBS disease.
Objective 4 – Acute costs of neonatal sepsis and meningitis.
Data from the sub-study on acute costs will be used to estimate the average length-of-stay, use of supportive care, drugs
and diagnostics, during hospitalization for the acute neonatal
sepsis/meningitis episode. These data will also be used to
calculate the overall cost per episode. Other variables will be
presented descriptively to characterize the impact of severe
neonatal infection.

Ethics
Written informed consent will be obtained from parents or guardians. Whenever appropriate, based on local guidelines, assent
will also be obtained from children participating in the study.
The overarching protocol for this multi-country observational
study was granted ethical approval at the London School of
Hygiene & Tropical Medicine (approval number 16246). Institutional review boards in each of the operating countries granted
ethics approval (Argentina approval number Protocol EGB-1,
India approval numbers 11723 (CMC Vellore), 2019–7034
(ICMR); Kenya approval number SERU/CGMR-C/164/3882;
Mozambique approval numbers 98/CNBS/2019; South Africa
approval number M190241), as well as the institutional review
board of the World Health Organization (approval number
ERC.0003169).

Discussion

This multi-country study will provide new data on the consequences of iGBS, which is responsible for significant morbidity, disability and mortality in infants9,17. In particular, we will
provide novel data on NDI and socioemotional and behavior
outcomes, especially in LMIC contexts. Previous reviews have

not included any low-income country data, outcomes due to
GBS-associated sepsis, or mild NDI15. Mild NDI may be common, impact families and societies, and are required to estimate
DALYs, which are widely used as metrics to set priorities for
resource allocation.
An important strength of this study is the inclusion of older
children (3–17 years) representing three continents (Latin America, Africa, Asia), which currently have limited local data on NDI,
socioemotional behavior outcomes, and wider socioeconomic
consequences following iGBS disease. This will allow better
understanding of the geographic variability on the risk of longterm disability linked to GBS. No previous studies have reported
on the potential long-term (>2 years) consequences of GBS
in these countries7. Furthermore, our study population will include
both children who developed sepsis and meningitis. Some studies
suggest that severe NDI might be lower in children developing sepsis compared to meningitis23,24. However, since sepsis
is more common among neonates with serious bacterial infection in LMIC settings5, even mild NDI could make an important contribution to the overall morbidity of iGBS. In addition
to the risk of long-term morbidity, iGBS may also lead to excess
mortality after the acute episode. Although our study is not
powered to compare mortality risk in iGBS survivors versus
those without history of iGBS, we will be able to describe
mortality and causes of deaths in four of five sites.
Another strength of our study is the collection of primary data
on healthcare use, income, and HRQoL across multiple countries, which will enable us to identify where iGBS disease may
lead to worse outcomes. Adverse economic outcomes due to
iGBS are thought to be likely, for example costs linked to sequelae that necessitates frequent healthcare utilization, costly
household adaptations, and additional time spent on caregiving
to support a child with disabilities21,25. However, to our knowledge,
only one study in the UK has directly measured the economic
costs of iGBS. In that study, where children were followed-up
to the age of two, the average health and social care costs were
substantially higher amongst those with history of iGBS13.
A major challenge of this study is the use of different developmental assessment tools in each country, and the complexity
of combining multi-domain and neurodevelopmental outcomes
for different age bands and multiple tests. We will try to
ensure measurement equivalence and comparability of the
NDI outcomes between different ages, assessment tools and
sites through domain mapping of assessment tools, before
individual-level data from each site is further combined for
analysis.
A further challenge is the impact that the global coronavirus
(COVID-19) pandemic will have on recruitment and research
activities, which are not clear. We will continue to assess the
situation and are working closely with research teams from each
and collaborative institutes to safely undertake field activities
in line with each country’s guidelines.
Findings from this study will be used to update previous morbidity estimates of the burden of infant iGBS disease12, adding
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relevant data on long-term outcomes. This will include information to estimate lifetime disability, including risk of NDI, and
societal impacts following GBS-related sepsis and meningitis.
These additional morbidity estimates, combined with the previously published data on mortality and morbidity of pregnant
and postnatal women and stillbirths, along with other literature,
will serve as data inputs for both mother and infant GBS disease to update estimates of the overall public health burden of
iGBS. Disease burden estimates will be translated into DALYs
incurred based on the latest available epidemiologic data, while
responses to the quality of life instruments combined with
mortality data will be used to estimate QALYs lost. These estimates
will be an important input feeding into future cost-effectiveness
analyses.
Our findings will contribute to a WHO value proposition on
GBS maternal immunization to inform strategic planning of
GBS vaccine research, development, and future implementation. Decision making by multiple stakeholders in the GBS
vaccine development process, including research funders, manufacturers, donors and national governments, will be shaped by
these findings. Data generated from this study will be linked
with research outputs providing more regional and country
specific details, allowing countries to utilize the findings in their
own context. This will help reduce the translational, marketing,
and implementation gaps for the development and introduction

of a new GBS vaccine in LMICs which experience some of
the highest disease burden.
Most of the mortality and morbidity of iGBS occurs in lowresource settings where there continues to be a paucity of data.
As well as the limited epidemiological and clinical data, there
are major gaps in data on the economic burden of both shortterm and the long-term effects of iGBS. Our study will address
limitations in the data currently available, providing new data on
epidemiological and economic outcomes are needed to get a
more complete picture on the consequences of iGBS for individuals and their families. Coordinated data collection across different settings together with harmonized analysis approaches,
will maximize the value of the collected data. The results of our
study will support development and investment in cost-effective
strategies to minimize the iGBS burden and improve the chances
for children to survive, thrive and reach their developmental
and economic potential.
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David Kaslow
Essential Medicines and Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA
The description of a multi-country protocol to quantify the acute costs and the long-term health
and economic outcomes of survivors of invasive GBS disease is clear, concise, and timely. The
rationale, that the results of this study provided essential input to a full value of vaccine
assessment (aka full public health value preposition, FPHVP), is also clear and convincing.
Two major questions come to this reviewer's mind when reading this manuscript:
1. Sample size and power calculation: this description appears to describe an approach for
determining whether there is a statistically significant difference between the iGBS survivors
group and the the matched non-iGBS control children for certain specific outcomes. That
there is a statistically significant difference between the two groups is certainly of some
interest, but would seem not to be the critical input data for a FPHVP assessment. Rather it
would seem that the critical information would be: 1) an absolute point estimate and
confidence intervals thereof of burden of disease outcomes that are the major value drivers
in the FPHVP; and 2) the excess burden of disease (see point 2 below) in iGBS survivors that
are the major value drivers in the FPHVP. Perhaps the data analyses and statistical
methodology that support these two estimates, with confidence intervals, is in the protocol,
but if not, the authors should be encouraged to add and describe those items.
2. Inclusion and exclusion criteria: Again, perhaps the information is provided in the protocol;
however, it is unclear what the inclusion and exclusion criteria of selecting iGBS survivors,
and equally important the case controls, with respect to other potential causes of the
endpoints being measured. For example, NDI is multifactorial, including both genetic and
infectious disease etiologies. Congenital CMV is a major, if not most frequent, cause of
neonatal infectious disease-associated NDI in high-income countries. While there are data
gaps in LMICs, accumulating evidence suggests CMV will also be a major contributor to
congenital/neonatal NDI. It would seem prudent that some attempt at capturing other
frequent causes of the endpoints studied, and either inclusion/exclusion criteria defined, or
at least stratified analyses of the data by those other causes (if known).
All in all, this multi-country study has a reasonable likelihood of collecting a critical set of input
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data for determining if and how compelling the FPHVP is for developing vaccines or other
interventions to protect against in utero, early and late onset iGBS.
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
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Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Yes
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expertise to confirm that it is of an acceptable scientific standard, however I have
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